Stay tuned for more information!
Despite numerous large studies over the past decade for patients with unresectable hepatocellular carcinoma (HCC), a second-line standard of care remained largely elusive following standard [...]
Prof. Richard Finn on Finding a Biomarker for Patients with HCC − Biomarker selection for systemic treatments has become a challenge in this particular field, Prof. Finn says.
Renew your membership or become a new member today and enjoy exclusive educational and networking benefits throughout 2017.
Discover the guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma which have published in the Journal of Hepatology.